(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3(Date:9/4/2008)...ctivity and favorable safety ...Newswire-FirstCall/ -- Idenix,Pharmaceuticals, Inc...gaged,in the discovery and development of drugs fo...s diseases, today announced that it has completed ...n-nucleoside reverse,transcriptase inhibitor (NNRT...
(Date:9/3/2008)...ll/ -- Simcere,Pharmaceutical Group (NYSE: SCR ),...neric pharmaceuticals and manufacturer of the pate...as Endostar) in China,announced the interim resul...st of the SFDA, Simcere initiated a Phase IV clini...peutic efficacy of Endu, a modified,version of rec...
(Date:9/3/2008)...Panacea Pharmaceuticals,Inc. today announced the ...antibodies against human aspartyl (asparaginyl) be...biomarker and therapeutic target. These antibodies...setts Institute of,Technology (MIT) and Panacea ha...evelopment of human cancer diagnostics and therape...
(Date:9/3/2008)...udy in Subjects with ALS, RICHMOND, Calif., Sept....Inc. (Nasdaq: SGMO ) announced today that it has ...aluate its drug, SB-509, in subjects,with ALS, a p...which there,are limited treatment options and no c...rmulation of a plasmid,encoding a zinc finger DNA-...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5After drought ponds keep up with the Joneses 808 1After drought ponds keep up with the Joneses 808 2After drought ponds keep up with the Joneses 808 3Studies Examine Life After Weight Loss Surgery 3715 1Studies Examine Life After Weight Loss Surgery 3715 2Studies Examine Life After Weight Loss Surgery 3715 3Studies Examine Life After Weight Loss Surgery 3715 4Baxter International Third Quarter 2007 Financial Results Conference Call 3712 1James B Hawkins Appointed to IRIDEX Board of Directors 3709 1James B Hawkins Appointed to IRIDEX Board of Directors 3709 2James B Hawkins Appointed to IRIDEX Board of Directors 3709 3...rstCall/ -- Vanda,Pharmaceuticals Inc. announced t... Sleep Disorders and Research Center in Detroit, M...se III clinical,trial results for VEC-162, Vanda,s... SLEEP 2007, the 21st annual meeting of the,Associ...anda presentation will take place at the Conventio...
...ation during the,early post-operative period compa...ction in nausea in the female,patient population c... - CeNeS Pharmaceuticals plc (AIM:,CEN), the Cambr...ditional data from post-hoc analysis of the recent...ronide) in over 500 patients,with post-operative p...
Other Medicine Technology:Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the,Annual Meeting of the Associated Professional Sleep Societies 2Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 2Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 3Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 4Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 5Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 6Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 7Elongated Loop, Slightly Curved; in Stainless Steel.
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM
AXIOM Artis TA is part of the AXIOM family, which introduces dynamic and efficient workflow into the clinical angiography, card- angiography, and neuroradiology procedures. On the clinical, technical
AXIOM Artis FA is a universal floor-mounted angiographic C-arm system whose flexible system architecture is ideal for vascular and non-vascular diagnostics and interventions. It provides complete erg
Medicine Products: